These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 27589575)

  • 1. Extracellular-signal regulated kinase 8 of Trypanosoma brucei uniquely phosphorylates its proliferating cell nuclear antigen homolog and reveals exploitable properties.
    Valenciano AL; Knudsen GM; Mackey ZB
    Cell Cycle; 2016 Oct; 15(20):2827-41. PubMed ID: 27589575
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery and antiparasitic activity of AZ960 as a Trypanosoma brucei ERK8 inhibitor.
    Valenciano AL; Ramsey AC; Santos WL; Mackey ZB
    Bioorg Med Chem; 2016 Oct; 24(19):4647-4651. PubMed ID: 27519462
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Depletion of the extracellular-signal regulated kinase 8 homolog in Trypanosoma brucei in vivo reduces its virulence in a mouse target validation study.
    Elaadli H; Kim I; Mackey ZB
    Mol Biochem Parasitol; 2018 Mar; 220():1-4. PubMed ID: 29287675
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Deviating the level of proliferating cell nuclear antigen in Trypanosoma brucei elicits distinct mechanisms for inhibiting proliferation and cell cycle progression.
    Valenciano AL; Ramsey AC; Mackey ZB
    Cell Cycle; 2015; 14(4):674-88. PubMed ID: 25701409
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Trypanosome alternative oxidase, a potential therapeutic target for sleeping sickness, is conserved among Trypanosoma brucei subspecies.
    Nakamura K; Fujioka S; Fukumoto S; Inoue N; Sakamoto K; Hirata H; Kido Y; Yabu Y; Suzuki T; Watanabe Y; Saimoto H; Akiyama H; Kita K
    Parasitol Int; 2010 Dec; 59(4):560-4. PubMed ID: 20688188
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phenotypic screen with Trypanosoma brucei for discovering small molecules that target the SLiM-binding pocket of proliferating cell nuclear antigen orthologs.
    Actis M; Fujii N; Mackey ZB
    Chem Biol Drug Des; 2024 Jan; 103(1):e14361. PubMed ID: 37767622
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Regulation and spatial organization of PCNA in Trypanosoma brucei.
    Kaufmann D; Gassen A; Maiser A; Leonhardt H; Janzen CJ
    Biochem Biophys Res Commun; 2012 Mar; 419(4):698-702. PubMed ID: 22387477
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel ERK-like, CRK-like protein kinase that modulates growth in Trypanosoma brucei via an autoregulatory C-terminal extension.
    Ellis J; Sarkar M; Hendriks E; Matthews K
    Mol Microbiol; 2004 Sep; 53(5):1487-99. PubMed ID: 15387824
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The cell cycle as a therapeutic target against Trypanosoma brucei: Hesperadin inhibits Aurora kinase-1 and blocks mitotic progression in bloodstream forms.
    Jetton N; Rothberg KG; Hubbard JG; Wise J; Li Y; Ball HL; Ruben L
    Mol Microbiol; 2009 Apr; 72(2):442-58. PubMed ID: 19320832
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of Trypanosoma brucei AdoMetDC Inhibitors Using a High-Throughput Mass Spectrometry-Based Assay.
    Volkov OA; Cosner CC; Brockway AJ; Kramer M; Booker M; Zhong S; Ketcherside A; Wei S; Longgood J; McCoy M; Richardson TE; Wring SA; Peel M; Klinger JD; Posner BA; De Brabander JK; Phillips MA
    ACS Infect Dis; 2017 Jul; 3(7):512-526. PubMed ID: 28350440
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cloning and characterization of a novel serine/threonine protein phosphatase type 5 from Trypanosoma brucei.
    Chaudhuri M
    Gene; 2001 Mar; 266(1-2):1-13. PubMed ID: 11290414
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Indirubin Analogues Inhibit
    Efstathiou A; Gaboriaud-Kolar N; Myrianthopoulos V; Vougogiannopoulou K; Subota I; Aicher S; Mikros E; Bastin P; Skaltsounis AL; Soteriadou K; Smirlis D
    Antimicrob Agents Chemother; 2019 Jun; 63(6):. PubMed ID: 30910902
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chemotherapeutic strategies against Trypanosoma brucei: drug targets vs. drug targeting.
    Lüscher A; de Koning HP; Mäser P
    Curr Pharm Des; 2007; 13(6):555-67. PubMed ID: 17346174
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The trans-sialidase from the african trypanosome Trypanosoma brucei.
    Montagna G; Cremona ML; Paris G; Amaya MF; Buschiazzo A; Alzari PM; Frasch AC
    Eur J Biochem; 2002 Jun; 269(12):2941-50. PubMed ID: 12071958
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 3-(Oxazolo[4,5-b]pyridin-2-yl)anilides as a novel class of potent inhibitors for the kinetoplastid Trypanosoma brucei, the causative agent for human African trypanosomiasis.
    Ferrins L; Rahmani R; Sykes ML; Jones AJ; Avery VM; Teston E; Almohaywi B; Yin J; Smith J; Hyland C; White KL; Ryan E; Campbell M; Charman SA; Kaiser M; Baell JB
    Eur J Med Chem; 2013 Aug; 66():450-65. PubMed ID: 23831695
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cloning and expression of the hypoxanthine-guanine phosphoribosyltransferase gene from Trypanosoma brucei.
    Allen TE; Ullman B
    Nucleic Acids Res; 1993 Nov; 21(23):5431-8. PubMed ID: 8265360
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Mitogen-activated protein kinase controls differentiation of bloodstream forms of Trypanosoma brucei.
    Domenicali Pfister D; Burkard G; Morand S; Renggli CK; Roditi I; Vassella E
    Eukaryot Cell; 2006 Jul; 5(7):1126-35. PubMed ID: 16835456
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Allosteric regulation of an essential trypanosome polyamine biosynthetic enzyme by a catalytically dead homolog.
    Willert EK; Fitzpatrick R; Phillips MA
    Proc Natl Acad Sci U S A; 2007 May; 104(20):8275-80. PubMed ID: 17485680
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glycogen synthase kinase 3 is a potential drug target for African trypanosomiasis therapy.
    Ojo KK; Gillespie JR; Riechers AJ; Napuli AJ; Verlinde CL; Buckner FS; Gelb MH; Domostoj MM; Wells SJ; Scheer A; Wells TN; Van Voorhis WC
    Antimicrob Agents Chemother; 2008 Oct; 52(10):3710-7. PubMed ID: 18644955
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Trypanosoma brucei CYP51: Essentiality and Targeting Therapy in an Experimental Model.
    Dauchy FA; Bonhivers M; Landrein N; Dacheux D; Courtois P; Lauruol F; Daulouède S; Vincendeau P; Robinson DR
    PLoS Negl Trop Dis; 2016 Nov; 10(11):e0005125. PubMed ID: 27855164
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.